Background and Objectives: During the coronavirus disease 2019 (COVID-19) pandemic, virtual visits (VVs) were recommended as an innovative and necessary alternative for patients with heart failure (HF). To assess the feasibility and acceptability of VVs in patients with HF, pulmonary hypertension (PH), and heart transplant (HT). Methods: We designed a single-centre cohort study. Consecutive VVs performed in our HF unit were analysed. The period comprehended between January 1st and March 19th (before COVID-19) and March 20th and June 30th (during COVID-19) was compared. We assessed acceptability, feasibility and the need for diagnostic studies, in-person medical evaluation, and hospitalization at 30 days. Results: HF unit medical doctors conducted 22 VVs in the pre-COVID period and 416 VVs during the COVID period. The VV was able to be performed in all patients scheduled for it and 44% answered the survey. Ninety percent of the patients who answered the survey strongly agreed that VVs were easy to be carried out. All the patients "strongly agreed" or "agreed" that their health problem could be resolved. Most patients (95%) rated the global experience as very good or excellent, with an overall average rate of 9.76±0.5 out of 10. We found no differences regarding the requirement of diagnostic studies, in-person medical evaluation and hospitalization during the first month after VVs between the 2 periods. Conclusions: VVs were feasible, presented high acceptability, and the overall experience was positive in patients with HF, PH, and HT, being this modality a valuable tool that complements in-person care.
Background and Objectives: During the coronavirus disease 2019 (COVID-19) pandemic, virtual visits (VVs) were recommended as an innovative and necessary alternative for patients with heart failure (HF). To assess the feasibility and acceptability of VVs in patients with HF, pulmonary hypertension (PH), and heart transplant (HT). Methods: We designed a single-centre cohort study. Consecutive VVs performed in our HF unit were analysed. The period comprehended between January 1st and March 19th (before COVID-19) and March 20th and June 30th (during COVID-19) was compared. We assessed acceptability, feasibility and the need for diagnostic studies, in-person medical evaluation, and hospitalization at 30 days. Results: HF unit medical doctors conducted 22 VVs in the pre-COVID period and 416 VVs during the COVID period. The VV was able to be performed in all patients scheduled for it and 44% answered the survey. Ninety percent of the patients who answered the survey strongly agreed that VVs were easy to be carried out. All the patients "strongly agreed" or "agreed" that their health problem could be resolved. Most patients (95%) rated the global experience as very good or excellent, with an overall average rate of 9.76±0.5 out of 10. We found no differences regarding the requirement of diagnostic studies, in-person medical evaluation and hospitalization during the first month after VVs between the 2 periods. Conclusions: VVs were feasible, presented high acceptability, and the overall experience was positive in patients with HF, PH, and HT, being this modality a valuable tool that complements in-person care.
Authors: Matthew D Solomon; Edward J McNulty; Jamal S Rana; Thomas K Leong; Catherine Lee; Sue-Hee Sung; Andrew P Ambrosy; Stephen Sidney; Alan S Go Journal: N Engl J Med Date: 2020-05-19 Impact factor: 91.245
Authors: Harlan M Krumholz; Angela R Merrill; Eric M Schone; Geoffrey C Schreiner; Jersey Chen; Elizabeth H Bradley; Yun Wang; Yongfei Wang; Zhenqiu Lin; Barry M Straube; Michael T Rapp; Sharon-Lise T Normand; Elizabeth E Drye Journal: Circ Cardiovasc Qual Outcomes Date: 2009-07-09
Authors: Ismail El-Hamamsy; Derek R Brinster; Joseph J DeRose; Leonard N Girardi; Kazuhiro Hisamoto; Mohammed N Imam; Shinobu Itagaki; Paul A Kurlansky; Christopher Lau; Samantha Nemeth; Mathew Williams; Benjamin A Youdelman; Hiroo Takayama Journal: J Am Coll Cardiol Date: 2020-05-15 Impact factor: 24.094
Authors: Michael E Hall; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Lampros Papadimitriou; Robert C Long; Gabriel A Hernandez; Charles K Moore; Brandon W Lennep; Michael R McMullan; Javed Butler Journal: J Card Fail Date: 2020-05-13 Impact factor: 5.712
Authors: Eiran Z Gorodeski; Parag Goyal; Zachary L Cox; Jennifer T Thibodeau; Rebecca E Reay; Kismet Rasmusson; Joseph G Rogers; Randall C Starling Journal: J Card Fail Date: 2020-04-18 Impact factor: 5.712
Authors: Daniel I Bromage; Antonio Cannatà; Irfan A Rind; Caterina Gregorio; Susan Piper; Ajay M Shah; Theresa A McDonagh Journal: Eur J Heart Fail Date: 2020-07-04 Impact factor: 17.349
Authors: Anthony C Smith; Emma Thomas; Centaine L Snoswell; Helen Haydon; Ateev Mehrotra; Jane Clemensen; Liam J Caffery Journal: J Telemed Telecare Date: 2020-03-20 Impact factor: 6.184